A feasibility study of Anthracycline-based regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for breast cancer.(SBCCSG-32)
Phase 2
- Conditions
- Primary breast cancer
- Registration Number
- JPRN-UMIN000012428
- Lead Sponsor
- Saitama Breast Cancer Clinical Study Group(SBCCSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) HER2 is positive by surgical specimen. 2) Pregnant or lactation women. 3) History of other malignancies within the last 5 years. 4) History of bilateral breast cancer 5) History of serious allergy 6) Patients judged by the investigator to be unfit to be enrolled into the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Feasibility
- Secondary Outcome Measures
Name Time Method Safety Overall survival Disease free survival Relation between Relative Dose Intensity (RDI) of Nab-Paclitaxel and Disease Free Survival ratio